دورية أكاديمية
Risk factors for oral mucositis during chemotherapy treatment for solid tumors: a retrospective STROBE-guided study.
| العنوان: | Risk factors for oral mucositis during chemotherapy treatment for solid tumors: a retrospective STROBE-guided study. |
|---|---|
| المؤلفون: | Martins JO; Ceará Cancer Institute Laboratory of Molecular Biology and Oncogenetics Papi Júnior Street, 1222, Rodolfo Teófilo 60351-010, Fortaleza, Ceará, Brazil cassiaemanuellan@gmail.com., Borges MM, Malta CE, Carlos AC, Crispim AA, Moura JF, Fernandes-Lima IJ, Silva PG |
| المصدر: | Medicina oral, patologia oral y cirugia bucal [Med Oral Patol Oral Cir Bucal] 2022 Jul 01; Vol. 27 (4), pp. e319-e329. Date of Electronic Publication: 2022 Jul 01. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Medicina Oral S.L Country of Publication: Spain NLM ID: 101231694 Publication Model: Electronic Cited Medium: Internet ISSN: 1698-6946 (Electronic) Linking ISSN: 16984447 NLM ISO Abbreviation: Med Oral Patol Oral Cir Bucal Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Valencia, España : Medicina Oral S.L., [2004]- |
| مواضيع طبية MeSH: | Head and Neck Neoplasms*/complications , Mucositis*/complications , Stomatitis*/chemically induced , Stomatitis*/epidemiology, Bevacizumab ; Carboplatin ; Female ; Humans ; Pain ; Retrospective Studies ; Risk Factors |
| مستخلص: | Background: This study retrospectively analyzed the risk factors for transchemotherapy oral mucositis (OM). Material and Methods: Before each chemotherapy cycle, patients were routinely evaluated for the presence/severity of OM based on the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 scale for adverse effects and graded as follows: However, specific conditions such as mucositis are graded on a five-point scale: 0, absence of mucositis, grade 1 (Asymptomatic or mild), 2 (Presence of pain and moderate ulceration, without interference with food intake), 3 (severe pain with interference with food intake) or 4 (Life-threatening with the need for urgent intervention). Information from 2 years of evaluations was collected and patient medical records were reviewed to obtain data on chemotherapy cycle, sex, age, body mass index, body surface area, primary tumor, chemotherapy protocol, and history of head and neck radiotherapy. The X² test and multinomial logistic regression were used for statistical analysis (SPSS 20.0, p<0.05). Results: Among 19,000 total evaluations of 3,529 patients during 5.32±4.7 chemotherapy cycles (CT) the prevalence of OM was 6.3% (n=1,195). Chemotherapy duration (p<0.001), female sex (p=0.001), adjuvant intention (p=0.008) and the use of carboplatin (p=0.001), cisplatin (p=0.029), docetaxel (p<0.001) and bevacizumab (p=0.026) independently increased the risk of mucositis. In head and neck tumors, 2018 year (p=0.017), chemotherapy duration (p=0.018), BMI>30 (p=0.008), radiotherapy (p=0.037) and use of carboplatin (p=0.046) and cyclophosphamide (p=0.010) increased this prevalence. Conclusions: Cycles of chemotherapy, sex, cytotoxicity drugs, bevacizumab and head and neck radiotherapy increase the risk of OM in solid tumors. |
| References: | PLoS One. 2014 Sep 08;9(9):e107418. (PMID: 25198431) Anticancer Res. 2021 Jan;41(1):1-7. (PMID: 33419794) Cancer Med. 2017 Dec;6(12):2918-2931. (PMID: 29071801) Oral Oncol. 2003 Feb;39(2):91-100. (PMID: 12509961) Support Care Cancer. 2000 Sep;8(5):366-71. (PMID: 10975685) Yakugaku Zasshi. 2017;137(2):221-225. (PMID: 28154335) Cancer. 2003 Oct 1;98(7):1531-9. (PMID: 14508842) J Clin Exp Dent. 2014 Feb 01;6(1):e81-90. (PMID: 24596641) Rev Saude Publica. 2010 Jun;44(3):559-65. (PMID: 20549022) Support Care Cancer. 2012 Jan;20(1):175-83. (PMID: 21331484) J Clin Oncol. 2014 Sep 20;32(27):2940-50. (PMID: 25154822) Int J Nurs Pract. 2019 Feb;25(1):e12710. (PMID: 30461128) Bull Cancer. 2016 Oct;103(10):861-868. (PMID: 27641463) Transl Cancer Res. 2020 Apr;9(4):3126-3134. (PMID: 35117676) Molecules. 2019 Aug 21;24(17):. (PMID: 31438508) Dent Clin North Am. 2014 Apr;58(2):341-9. (PMID: 24655526) Ann Oncol. 2018 May 1;29(5):1130-1140. (PMID: 29635316) Actas Dermosifiliogr (Engl Ed). 2021 Jan;112(1):90-92. (PMID: 32891586) Acta Oncol. 2012 Apr;51(4):490-6. (PMID: 22129358) Support Care Cancer. 2018 Nov;26(11):3883-3889. (PMID: 29754211) Support Care Cancer. 2006 Jun;14(6):505-15. (PMID: 16601950) Support Care Cancer. 2013 Jul;21(7):2075-83. (PMID: 23604521) Head Neck. 2005 May;27(5):421-8. (PMID: 15782422) CA Cancer J Clin. 2017 Mar;67(2):93-99. (PMID: 28094848) Cancer Nurs. 2004 Jan-Feb;27(1):71-8. (PMID: 15108954) Support Care Cancer. 2010 Nov;18(11):1477-85. (PMID: 19916030) Radiother Oncol. 2003 Mar;66(3):253-62. (PMID: 12742264) |
| المشرفين على المادة: | 2S9ZZM9Q9V (Bevacizumab) BG3F62OND5 (Carboplatin) |
| تواريخ الأحداث: | Date Created: 20220619 Date Completed: 20220628 Latest Revision: 20220716 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC9271342 |
| DOI: | 10.4317/medoral.25253 |
| PMID: | 35717621 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1698-6946 |
|---|---|
| DOI: | 10.4317/medoral.25253 |